Agomab Therapeutics NV filings document the company's foreign private issuer reports, ADS public offering disclosures, governance materials, and clinical-stage biopharmaceutical updates. Form 6-K reports have included the closing of the company's initial public offering of American Depositary Shares, amended and restated articles of association, press releases, annual meeting materials, proxy forms, and voting documentation.
AGMB's regulatory record also discloses capital-structure matters tied to ADSs and common shares, incorporation of materials into a Form S-8 registration statement, financial results, business updates, shareholder voting matters, and clinical or regulatory disclosures related to its fibro-inflammatory disease programs.
Agomab Therapeutics NV’s Chief Financial Officer Pierre Thadee Victor Kemula reported existing stock option holdings in a Form 3. The filing shows three option awards over 289,005, 102,057 and 191,958 common shares at exercise prices of $2.7600, $3.1800 and $14.2600, expiring between July 8, 2034 and January 15, 2036. Footnotes describe time-based vesting, including one grant where 50% of the underlying shares vested on February 9, 2026 with the balance vesting in 24 monthly installments, and another where 25% vests on February 9, 2027 followed by 36 monthly installments. The options relate to common shares, which may be represented by American Depositary Shares on a one-for-one basis.
Agomab Therapeutics director Angelika Martha Jahreis reported her existing stock option holdings in a Form 3. She holds several options over common shares, including 94,438 shares at an exercise price of $3.10 per share expiring on October 10, 2033. Other options cover 1,884, 27,165 and 31,505 underlying shares with exercise prices from $2.81 to $14.26 and expirations between July 8, 2034 and January 15, 2036. Footnotes state some options are fully vested, while others vest in scheduled monthly installments from February 9, 2026 and February 9, 2027, contingent on continued service.
Agomab Therapeutics NV Chief Business Officer Paul Henryk van der Horst has reported his derivative equity holdings in a Form 3. The filing lists several stock options to buy Agomab common shares at exercise prices of $0.0005 and $14.2600 per share.
The options cover different blocks of underlying common shares, with expiration dates ranging from 2031-03-05 through 2036-01-15. Footnotes state that some shares underlying these options are fully vested and exercisable, while others vest over time in monthly installments, subject to his continued service.
Agomab Therapeutics NV director Verduyn-van Weegen Felice Isabel reported an initial stock option holding for 32,700 common shares. The option has an exercise price of $14.2600 per share and expires on January 15, 2036.
According to the filing, 33% of the underlying shares vest on February 9, 2027, with the remainder vesting in 24 equal monthly installments, subject to continued service. The common shares may be represented by American Depositary Shares, each currently representing one common share.
Agomab Therapeutics NV filed an initial ownership report for Chief Development Officer Andrea Saez Borderias, detailing multiple stock option awards over common shares. The options are held directly, with exercise prices of $0.0005 and $14.2600 per share and expirations ranging from 2031 to 2036. Footnotes state that some options are already fully vested and exercisable, while others vest over time in scheduled monthly installments, conditioned on continued service. The common shares may also be represented by American Depositary Shares on a one-for-one basis.
Agomab Therapeutics NV General Counsel Ellen Lefever filed an initial statement of beneficial ownership, detailing several stock option awards over common shares. These options give rights to buy AGMB shares at exercise prices including $2.7600, $3.1800 and $14.2600, with expirations from 2031 through 2036.
One grant covers 91,256 underlying common shares at $2.7600 per share expiring on March 5, 2031, and another covers 127,972 shares at $14.2600 expiring on January 15, 2036, all held directly. Footnotes note that some options are fully vested while others vest over time, that common shares may be represented by ADSs on a 1:1 basis, and that exercise prices are reported in U.S. dollars using a stated EUR/USD exchange rate.
Agomab Therapeutics NV Chief Medical Officer Philippe Constantin Wiesel reported his initial holdings of stock options on the company’s common shares. The filing lists ten option grants with exercise prices between $0.0005 and $14.26, expiring from 2029 through 2036. Footnotes explain which grants are already fully vested and which vest over time, and note that each American Depositary Share currently represents one common share.
Agomab Therapeutics ownership update: FMR LLC reports beneficial ownership of 4,873,680 shares, representing 10.0% of common stock as of the filing. The Schedule 13G shows sole dispositive and voting power reported by FMR LLC and dispositive power reported for Abigail P. Johnson.
The filing is a Schedule 13G disclosure, signed under powers of attorney and accompanied by Exhibit 99 referencing a 13d-1(k)(1) agreement; the signatures are dated 03/05/2026.
AgomAb Therapeutics NV received a Schedule 13D filing from investment entities LSP 7 Cooperatieve U.A. and LSP 7 Management B.V., which together report beneficial ownership of 5,141,992 common shares, representing about 10.6% of AgomAb’s 48,736,779 common shares outstanding as of February 9, 2026.
LSP 7 accumulated its position through pre-IPO preferred stock purchases of approximately €40 million that converted into 4,016,992 common shares at the IPO, plus a purchase of 1,125,000 American Depositary Shares at $16.00 per share on the IPO closing date. The investors are party to an amended and restated shareholders’ agreement providing registration rights for resale of certain shares and have agreed to a 180‑day lock-up restricting sales after the IPO closing.
The filing states that the investors may, from time to time, buy more shares, hold, or sell, and may discuss strategic alternatives with AgomAb’s management, board, other shareholders, and third parties, potentially including mergers, asset transactions, capital structure changes, or board composition changes. One of their designees, Felice Verduyn‑van Weegen, serves on AgomAb’s board of directors.